What severe respiratory disease teaches us about vaccine design: the expanding reach of Matrix-M

“Durability informs those priorities because the predominantly Th1-biased response Matrix-M generates is relevant to the quality and length of protection and shapes our antigen and adjuvant design across the pipeline.”

Ashling Cannon, Editor, Vaccine Insights , speaks with Robert Walker, Executive Vice President, Head of Research & Development, Novavax, about how a clinical background in pulmonary and critical care medicine shapes Novavax’s approach to vaccine immunology. They discuss the mechanistic basis for their technology’s tolerability profile, the expanding utility of the Matrix-M adjuvant across infectious disease and oncology, H5N1 pandemic preparedness strategy, the early-stage Clostridioides difficile (C. difficile) program, and Novavax’s research priorities following the transition of Nuvaxovid commercialization to Sanofi.

Please enter your email to access content Read now